1. Venook AP, Ou FS, Lenz HJ, Kabbarah O, Qu X, et al. Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2017;35:abstr3503.
2. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
4. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
5. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
6. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457-67.
7. Ciardiello FL, Lenz HL, Kohne CH, Heinemann V, Tejpar S, et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014;32:abstr3506.
8. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015;51:1243-52.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
10. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
11. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
12. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
13. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
14. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22-8.
15. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011;29:2675-82.
16. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
17. Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014;20:744-53.
18. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75.
19. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902-12.
20. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013;14:749-59.
21. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015;51:587-94.
22. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015;112:1888-94.
23. Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 2013;18:670-7.
24. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011;17:4901-14.
25. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011;6:e15980.
26. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
27. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
28. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014;53:852-64.
29. Mohamed A, Twardy B, AbdAllah N, Akhras A, Ismail H, et al. Clinical impact of PI3K/BRAF mutations in RAS wild metastatic colorectal cancer: meta-analysis results. J Gastrointest Cancer 2018; doi: 10.1007/s12029-018-0062-y.
30. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A 1991;88:7792-6.
31. Li XD, Miao SY, Wang GL, Yang L, Shu YQ, et al. Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics. Onkologie 2010;33:353-8.
32. Chayangsu C, Khunsri S, Sriuranpong V, Tanasanvimon S. The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer. J Gastrointest Oncol 2017;8:980-4.
33. Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, et al. Amphiregulin and epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer 2012;12:88.
34. Oliveras-Ferraros C, Cufi S, Queralt B, Vazquez-Martin A, Martin-Castillo B, et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer 2012;106:1406-14.
35. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, et al. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol 1992;118:741-51.
36. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
37. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
38. Jing C, Jin YH, You Z, Qiong Q, Jun Z. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. Oncotarget 2016;7:55890-9.
39. Jonker DJ, Karapetis CS, Harbison C, O’Callaghan CJ, Tu D, et al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 2014;110:648-55.
40. Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, et al. Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer. JAMA Oncol 2016; doi: 10.1001/jamaoncol.2015.6065.
41. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322-30.
42. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
43. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
44. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-40.
45. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, et al. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 2009;29:1615-20.
46. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
47. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
48. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
49. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773-9.
50. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016;29:1104-12.
51. Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 2016;29:1433-42.
52. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014;23:2965-70.
53. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-42.
54. Wang HB, Yao H, Li CS, Liang LX, Zhang Y, et al. Rise of PD-L1 expression during metastasis of colorectal cancer: implications for immunotherapy. J Dig Dis 2017;18:574-81.
55. Lim YJ, Koh J, Kim S, Jeon SR, Chie EK, et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8(+) tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys 2017;99:1216-24.
56. George TJ, Frampton GM, Sun J, Gowen K, Kennedy M, et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. J Clin Oncol 2016;34:abstr3587.
57. Ali SM, Gay LM, Elvin JA, Vergilio J, Ramkissoon SH, et al. MSI-high and MSI-stable colorectal carcinomas (CRC): a comprehensive genomic profiling (CGP) study. J Clin Oncol 2018;36:abstr3574.
58. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
59. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011;128:2075-84.
60. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
61. Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2013;15:e711-8.
62. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
63. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
64. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015;33:4032-8.
65. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726-36.
66. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
67. Kopetz C, McDonough SL, Morris VK, Lenz HJ, Magliocco AM, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017;35:abstr520.
68. van Geel R, Tabernero J, Elez E, Bendell JC, Spreafico A, et al. A phase Ib dose-escalation study of Encorafenib and Cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 2017;7:610-9.
69. Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33:abstr103.
70. Richman SD, Southward K, Chambers P, Cross D, Barrett J, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 2016;238:562-70.
71. Lee WS, Park YH, Lee JN, Baek JH, Lee TH, et al. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med 2014;3:674-80.
72. Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, et al. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Oncotarget 2016;7:3453-60.
73. Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015;28:1481-91.
74. Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. J Clin Oncol 2017;35:abstr676.
75. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst 2017;109.
76. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase i trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017;7:400-9.
77. Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer 2015;113:1730-4.
78. Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst 2016;108.
79. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454.
80. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012;30:2956-62.
81. Bertucci F, Finetti P, Guille A, Adelaide J, Garnier S, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget 2016;7:27208-19.
82. Haraldsdottir S, Roth R, Pearlman R, Hampel H, Arnold CA, et al. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Fam Cancer 2016;15:253-60.
83. Jung J, Kang Y, Lee YJ, Kim E, Ahn B, et al. Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry. J Pathol Transl Med 2017;51:129-36.
84. Agoston EI, Baranyai Z, Dede K, Bodoky G, Kulka J, et al. Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases. Orv Hetil 2015;156:1460-71.
85. Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014;135:2215-22.
86. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-5.
87. Bachet JB, Bouche O, Taieb J, Dubreuil O, Garcia ML, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol 2018;29:1211-9.
88. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015;26:1715-22.
89. Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, et al. Early evaluation of circulating tumor dna as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res 2017;23:5416-25.
90. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.